An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®

A 24-month Prospective, Non-interventional, Observational Study on the Composite Clinical Endpoint (GET-Score) Reflecting Quality of Life, Body Composition and Cholesterol Metabolism in Patients Treated With Norditropin® (Somatropin)

This observational study is conducted in Europe. The aim of this observational study is to investigate the changes in a score (GET-score) which includes quality of life, body composition and cholesterol metabolism in patients on growth hormone treatment. The GET score stands for: Growth hormone deficiency and Efficacy of Treatment, and is a quantitative measurement of the efficacy of the treatment with growth hormone in adults.

Inclusion Criteria:

• Severe acquired growth hormone deficiency
• No treatment with somatropin in the last 24 months before study participation
• Written informed consent

Exclusion Criteria:

• Contraindications for the treatment with somatropin